NASDAQ:ATHE Alterity Therapeutics Q4 2026 TU Earnings Results & Report $2.09 -0.06 (-2.79%) Closing price 10/23/2026 03:59 PM EasternExtended Trading$2.08 -0.01 (-0.48%) As of 10/23/2026 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Alterity Therapeutics was expected to report Q4 2026 TU earnings on August 28, 2026, before market opens. Analysts expected earnings of -$0.1218 per share on revenue of $2.32 million. Confirmed results have not been posted yet. This page will update with the reported figures, conference call transcript, and earnings documents as they become available. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ4 2026 TUAnnouncement DateAugust 28, 2026TimeBefore Market Opens Alterity Therapeutics EPS ResultsActual EPSN/AConsensus EPS -$0.1218Beat/MissN/AOne Year Ago EPSN/AAlterity Therapeutics Revenue ResultsActual RevenueN/AExpected Revenue$2.32 millionBeat/MissN/AYoY Revenue GrowthN/AConference Call ResourcesPress ReleaseEarnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release Alterity Therapeutics Earnings HeadlinesAlterity Therapeutics to Present at the Canaccord Genuity Drug and Device ConferenceOctober 9, 2026 | globenewswire.comAlterity Therapeutics Presents New Analyses of ATH434 Phase 2 Data in Multiple System Atrophy at the 2026 International Congress of Parkinson’s Disease and Movement DisordersOctober 5, 2026 | finance.yahoo.comHere’s Why Trump Won’t End The Iran WarTrump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. One day it's a ceasefire, the next it's bombs again. The back and forth may be masking a bigger story most investors are missing. See the real reason this conflict may never fully end.October 25 at 1:00 AM | Banyan Hill Publishing (Ad)Alterity's ATH434 Demonstrates Slower MSA Progression In Phase 2October 5, 2026 | rttnews.comAlterity Therapeutics Reports New ATH434 Data In MSAOctober 5, 2026 | rttnews.comAlterity Therapeutics Presents New Analyses of ATH434 Phase 2 Data in Multiple System Atrophy at the 2026 International Congress of Parkinson's Disease and Movement DisordersOctober 5, 2026 | globenewswire.comSee More Alterity Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Alterity Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Alterity Therapeutics and other key companies, straight to your email. Email Address About Alterity TherapeuticsAlterity Therapeutics (NASDAQ:ATHE) Limited (NASDAQ: ATHE) is a clinical-stage biotechnology company focused on developing treatments for neurodegenerative diseases. The company’s research centers on abnormal protein accumulation and misfolding, biological processes associated with conditions such as Parkinson’s disease and Alzheimer’s disease. Alterity’s lead investigational therapy is buntanetap, formerly known as PBT434. The small-molecule drug is designed to inhibit the formation of toxic misfolded proteins, including alpha-synuclein and tau, with the goal of slowing or preventing disease progression. Buntanetap has been evaluated in clinical studies involving patients with neurodegenerative disorders, including Parkinson’s disease. The company was formerly known as Prana Biotechnology and adopted the Alterity Therapeutics name in 2018. It is headquartered in Melbourne, Australia, and conducts research and clinical development activities internationally, including in the United States. Alterity’s securities trade on the Australian Securities Exchange under the symbol ATH and on the Nasdaq under the symbol ATHE.View Alterity Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 10/19 - 10/23Amex Stock Slides on Job Cuts, But the Real Story Is MacroBloom Energy Just Reported—Its Biggest Order Is Still Waiting on a PipelineLockheed Martin’s Record $292 Billion Backlog Comes With a Delivery TestCan Planet Fitness Get Its Growth Back in Shape?Spotify Soars After Earnings as the Company Touts AI Benefits and Moderating CostsWhy Western Digital's AI Storage Boom Defies the Chip Sell-Off Upcoming Earnings Verizon Communications (10/26/2026)Nucor (10/26/2026)Public Storage (10/26/2026)Welltower (10/26/2026)Cadence Design Systems (10/26/2026)Hilton Worldwide (10/27/2026)Royal Caribbean Cruises (10/27/2026)CocaCola (10/27/2026)Coca Cola Femsa (10/27/2026)Baker Hughes (10/27/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
